Thalidomide is best known as a potent teratogenic agent but has been used sporadically to treat a variety of immunologically mediated disorders. Recently, thalidomide has been shown to be an effective agent in both treating and preventing graft-v-host disease (GVHD) after bone marrow transplantation (BMT) in a rat major histocompatibility mismatched model. The present report describes our results using combination low-dose thalidomide and low-dose cyclosporine prophylaxis in this model of GVHD.
|Original language||English (US)|
|Number of pages||3|
|Issue number||2 SUPPL. 2|
|State||Published - 1988|
ASJC Scopus subject areas